This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap
by Sweta Killa
Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs having the largest exposure to the drug maker could be compelling picks to tap the strong growth.
5 ETFs to Buy on JNJ's Q2 Earnings Strength
by Sweta Killa
Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
UnitedHealth Beats Q2 Earnings, Updates View: ETFs to Gain
by Sweta Killa
UnitedHealth (UNH) reported better-than-expected second-quarter 2023 results, breezing past the Zacks Consensus Estimate for earnings and revenues. The company lifted the lower end of its full-year earnings guidance.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
The Zacks Analyst Blog Highlights XHB, FXR, XLP and IYH
by Zacks Equity Research
XHB, FXR, XLP and IYH are part of the Zacks top Analyst Blog.
4 Top-Ranked Sector ETFs to Buy in the Second Half
by Sweta Killa
Investors could be well served by ETFs from sectors that house the top-ranked industries.
The Zacks Analyst Blog Highlights VYM, SPYD, IYH, XLP and FTCS
by Zacks Equity Research
VYM, SPYD, IYH, XLP and FTCS are part of the Zacks top Analyst Blog.
5 ETF Underdogs of 1H Likely to Turnaround in 2H
by Sanghamitra Saha
The Wall Street rally in the first half of 2023 involved a narrow market breadth. Hence, there were many ETF under-performers. But these ETFs could rebound in the second half.
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
by Sweta Killa
Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.